Ginkgo Bioworks (NYSE: DNA)
Ginkgo Bioworks Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Ginkgo Bioworks Company Info
Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.
News & Analysis
These Are Billionaires’ Favorite Healthcare Stocks
The Motley Fool analyzed 16 billionaire-led hedge funds to get an idea of their healthcare sector investment strategies.
What's the Difference Between Biotech Stocks and TechBio Stocks?
A few enterprising businesses are marketing themselves differently.
Ginkgo's Q1 Earnings Were a Mixed Bag
The cell engineering and biosecurity specialist's sales slumped as a big source of COVID-related revenue dried up.
Ginkgo Bioworks: Buy, Sell, or Hold?
This company has a long way to go before investors will see rewards.
The AI Advantage: 2 Healthcare Stocks at the Forefront of Innovation
They might not be profitable yet, but they're swinging for the fences.
2 Stocks That Could More Than Double Your Money, According to Wall Street: Are They Buys Now?
These stocks could rocket higher, but they also present significant risks.
Is Ginkgo Bioworks Stock a Buy?
There's a lot to like about this business, but it's still a risky bet.
Is Ginkgo Bioworks Destined to Be in a "Magnificent Seven" of Healthcare Stocks?
It isn't ready for membership today, but it could have a path in the future.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.